Drug Profile
Entinostat - Syndax Pharmaceuticals
Alternative Names: EDP-103; Entinostat; EOC 103; KHK-2375; MS-27-275; MS-275; SND 275; SNDX-275Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nihon Schering; Pfizer; University of Tokyo
- Developer Bristol-Myers Squibb; Columbia University; Eddingpharm; Genentech; Hoosier Cancer Research Network; Indiana University; Kyowa Kirin; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Pfizer; Syndax Pharmaceuticals; UNC Lineberger Comprehensive Cancer Center
- Class Aniline compounds; Antineoplastics; Benzamides; Carbamates; Pyridines; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; HER2 negative breast cancer; Hodgkin's disease; Leukaemia; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Uveal melanoma
Most Recent Events
- 31 Jul 2023 Syndax Pharmaceuticals and UNC Lineberger Comprehensive Cancer Center completes the phase II trials for Malignnant melanoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT03765229)
- 08 Jun 2023 Efficacy and safety data from a phase Ib trial for Myelodysplastic syndromes and Acute myeloid leukemia presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 02 Jun 2023 Syndax Pharmaceuticals halts enrolment in a Phase-II clinical trials in Renal cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) due to unforeseen circumstances prior to June 2023 (NCT03501381)